Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. - Physician's Weekly

About The Expert

David A Braun

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Yue Hou

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA.

Ziad Bakouny

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

Miriam Ficial

Harvard Medical School, Boston, MA, USA.

Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA.

Miriam Sant’ Angelo

Harvard Medical School, Boston, MA, USA.

Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA.

Juliet Forman

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA.

Petra Ross-Macdonald

Bristol-Myers Squibb, Princeton, NJ, USA.

Ashton C Berger

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Opeyemi A Jegede

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Liudmilla Elagina

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

John Steinharter

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Maxine Sun

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Megan Wind-Rotolo

Bristol-Myers Squibb, Princeton, NJ, USA.

Jean-Christophe Pignon

Harvard Medical School, Boston, MA, USA.

Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA.

Andrew D Cherniack

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Lee Lichtenstein

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Donna Neuberg

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Paul Catalano

Harvard Medical School, Boston, MA, USA.

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.

Gordon J Freeman

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

Arlene H Sharpe

Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.

David F McDermott

Harvard Medical School, Boston, MA, USA.

Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Eliezer M Van Allen

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Sabina Signoretti

Harvard Medical School, Boston, MA, USA.

Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA.

Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.

Catherine J Wu

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. cwu@partners.org.

Harvard Medical School, Boston, MA, USA. cwu@partners.org.

Broad Institute of MIT and Harvard, Cambridge, MA, USA. cwu@partners.org.

Sachet A Shukla

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. sachet_shukla@dfci.harvard.edu.

Broad Institute of MIT and Harvard, Cambridge, MA, USA. sachet_shukla@dfci.harvard.edu.

Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA. sachet_shukla@dfci.harvard.edu.

Toni K Choueiri

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.

Harvard Medical School, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.

References

PubMed